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Tvvo patients with histologically proven tnycosis fun-
goides, a tnalignancy of phenotypically mature T 
cells, received a topical challenge with mechloreth-
a lDine to areas of clinically uninvolved skin to ex-
clude possible hypersensitivity reactions to this 
ch emotherapeutic agent. In both patients, allergic 
contact dertnatitis (ACD) developed at the sites of the 
application and resolved completely after withdrawal 
of mechlorethatnine. The lesions were biopsied and 
analyzed for the presence of clonal T-cell receptor 
(TCR)-y gene rearrangements using two polytnerase 
chain reaction (pCR)-based assays involving denatur-
ing gradient gel electrophoresis (PCRlDGGE) and 
ribonuclease protection analysis (PCRlRPA). The 
former method has a clonal detection threshold of 
10-3_10-2 , while the latter has a sensitivity of10-5 • In 
b oth cases, the ACD lesions were polyclonal by PCRI 
DGGE. In contrast, PCRlRPA detected tumor-spe-
cific TCR-y gene rearrangements in these same le-
sions. This indicates that the ACD lesions contained 
tUlDor cells at a density within the 10-5-10- 2 range. 
Analysis of peripheral blood mononuclear cells from 
M ycosis fungoides (MF) is characterized by a clonal expansion of phenotypically mature T cells belonging to the skin-associated lymphoid tissue (SALT) (Bos, 1990). The typical pheno-type is that ofa CD4 +CD45RO + CLA+ m em-
ory T ce ll (Wood, 1992; H eald el aI, 1993). The malignant clone of 
MF generally contains uniform rearrangem ents of T-cell receptor 
(T CR)-y gen es (Wood et aI, 1994). The individual rearrangements 
vary not only by the usage of different variable (V) and joining 0) 
ge n e segments, but by virtually unique sequences of nucleotides at 
the junction of the participating segmen ts-the combined result of 
small deletions of basepairs from the ends o f the rearranging 
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both patients failed to detect the tnalignant clone and 
showed the same result as blood from four normal 
individuals. The normal skin from one patient also 
lacked detectable TCR-y gene rearrangements. These 
results indicate that tnycosis fungoides tUtnor cells are 
present within ACD lesions induced in mycosis fun-
goides patients and that this phenotnenon does not 
appear to be due to the ubiquitous presence of detect-
able levels of these tUtnor cells in the blood or skin. 
These findings might be explained by nonspecific re-
cruitment of malignant T cells to sites of local inflam-
mation mediated by non-neoplastic antigen-specific T 
cells. Alternatively, they might be due to the local 
proliferation of very rare tumor cells in apparently 
normal skin in response to cytokines generated during 
the ACD reaction. In either case, the present study 
offers evidence that the malignant cells in mycosis 
fungoides retain at least sotne capability of responding 
in vivo to physiologic stimuli. Key wOI'ds: mycosisfimgoidesl 
allel1lic contact demlatitisIT-cell,'eceptOl'IPCR, ] Invest Del'l11a-
tol106:685-688, 1996 
segments and the insertion of short stretches of random basepairs 
(so-called N region sequences) between the segments prio r to 
joining. The individual TCR-y gene rearrangement, including the 
sequence at the V / N /] junction, can therefore be regarded as a 
specific genotypic m arker for the cells comprising the m alignant 
clone in MF (Wood et ai, 1994). 
W e have previously employed tw o sensitive molecular biologic 
m ethods to detec t clonally rearranged TCR-y genes in specimens 
obtained from MF patients . Both inv olve polym erase chain reaction 
(PCR)-based amplification of TCR-y gene rearrangem ents fol-
lowed by either denaturing gradient gel electrophoresis (the PCRI 
DGGE assay) (Wood et ai , 1994) or ribonuclease protection an alysis 
(the PCR/ RPA assay) (Veelken et ai , 1995) . Both assays detect 
tumor-specific TCR-y gen e rearrangem ents based on their unique 
V / N I ] sequences. PCR/ DGGE has a sensitivity limit of 10- 3 _ 
10 - 2 , willie PCRlRPA has a sensitivity limit of 10 - 5 . As a con-
sequence , these two assays can provide complementar y information 
regarding tumor clone den sity within MF patient sanlples. 
In this report, w e describe the use o f these assays in tw O patients 
with MF to detect the presence of their malignant T-cell clones in 
lesions of allergic contact dermatitis (A CD) induced by m echlor-
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ethamine. Topical mechlorethamine is one of the mltior treatments 
for patch/plaque MF and its major side effect is allergic contact 
dcrmatiti s (Haserick ef ai, 1959; Waldorf et ai, 1967; Van Scott and 
K almanson, 1973; Constantine et ai, 1975; Price et ai, 1977; Price et 
ai, 1983; Vonderheid, 1984; Ramsay ef ai, 1988; Vonderheid et ai, 
1989). Our results indicate that MF tumor cells have the ab ility to 
participate in ACD reactions at low levels. This probably reflects 
their generally well-differentiated n ature. 
METHODS 
Patients Patient 1 was a 43-year-old white female with newly diagnosed 
stage III MF, although she reported her skin lesions began 20 years earlier. 
At the time of study, her MF lesions consisted of generalized poikiloder-
matous patches. Prior treatment included topical corticosteroids and ultra-
violet B phototherapy. Patient 2 was a 73-year-old white female with a 
19-year history ofMF that was originally stage lIB . At the time of study, her 
MF lesions consisted of generalized thin plaques. Prior treatment included 
topica l corticos teroids, localized electron beam therapy, localized ortho-
voltage radiation therapy and psora len plus ultraviolet A phototherapy. 
Both patients were diagnosed using standard clinicopathologic criteria 
(Wood, 1992). Neither patient was undergoing treatment at the time of 
testing with 10 mg')'o mechlorethamine oinm1ent applied nightly to a small 
area of uninvolved skin on one volar forearm. Within 1 wk, both patients 
developed allergic contact dermatitis manifested by pruritus, erythema 
edema, and mild vesiculation restricted to the site of mechlorethamine 
application. The test reaction subsided completely within 2-3 wk after 
discontinuing mechlorethamine. There was no appreciable change in either 
patient's MP lesions throughout this testing period. 
Samples All biopsies were performed with informed consent and use of 
human subjects received committee approval. Peripheral venous blood and 
skin biopsies of the positive test site and distant MP lesions were obtained 
from both patients . In addition, a distant clinically normal skin biopsy was 
collected from Patient 1. Except for the lesional MP specimens from Patient 
1, which were obtained about 1 month earlier, aU specimens within each 
case were obtained concurrently 1 wk after beginning the nightly mechlor-
ethamine use test. Normal peripheral venous blood was obtained from 
healthy volunteers. Mononuclear cells from blood specimens were pnrified 
by PicoU density gradient centrifugation. All samples were cryopreserved at 
- 70·C until further processing. DNA was extracted using routine proce-
dures (Wood et ai, 1994; Veclken et ai, 1995). 
PCRlOGGE C lonal TCR-y gene reatrangements involving Vy1-9 and 
Jy1-2 were detected by two-round PCR using nested primer pairs followed 
by separation of PCR products in a denaturing gradient gel. The details of 
this method have been published previously (Wood ef ai, 1994). In this 
assay, ethidium bromide-stained gels exhibit a diffuse smear in lanes 
containing PCR products amplified from polyclonal T cell s, while one or 
more distinct bands are present in lanes containing PCR products derived 
from T cells containing a dominant TCR-y gene rearrangement . Further-
more, a matching band pattern in different lanes reflects an identical clonal 
TCR-y gene rearrangement in the respective DNA samples. Titration 
studies using normal keratinocytes and tonsil cells have shown a sensitivity 
limit of 10- '-10- 2 for detection of a dominant T-cell clone (Wood et ai, 
1994). 
PCRlRPA T umor-specific TCR-y rearra ngements involving Vy1-B and 
Jyl-2 were also detected using a second method known as PCR/Rl'A 
which has been described in detail previously (Veclken ef ai, 1995). An 
RNA probe for the clonal TCR-y gene rearrangement was constructed by 
first amplifYing DNA from the biopsy diagnostic for MP by PCR for 30 
cycles using oligonucleotide primers complementary to conserved se-
quences in the Vy1-B and Jy1-2 segments of the TCR-y gene. The 
J y-specific primer carries at its 5' end the promoter for T7 RNA polymer-
ase . The incorporation of this promoter into the PCR product allows 
efticient ill vitro transcription of the PCR product. Transcription in the 
presence of [a-32PjUTP yielded a radiolabeled, anti-sense RNA probe 
specific fo r the malignant T-cell clone. 
Unlabeled tcst RNA in sense orientation was synthesized in an analogous 
manner from the TCR-y gene rearrangements found in the DNA of the 
ACO specimen, peripheral blood mononuclear cells (PBMC) from the 
patients, and PBMC from four healthy control donors. The normal skin 
specimen did not contain TCR-y gene rearrangements amplifiable with the 
Vy1-B and Jyl-2 primers. The Vy-specific primer in this set of PCR 
reactions carries the T7 promoter. The J y-specific primer of this reaction 
binds to the J'Y segment in a position upstream of the primer used for 
synthesis of the probe. Test RNA and probe RNA were hybridized together 
under highly stringent conditions (B5°;', formamide; 64·C). Mismatched 
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Figure 1. PCRlOGGE detects clonal TCR-y gene rearrangements 
in MF lesions but not in ACO lesions induced in two MF patients. 
Lallrs 1-3, Patient 1; lalles 4- 7, Patient 2; lalles 8 and 9, polyclonal control. 
See text for details. 
pyrimidine residues in the resulting I~A heteroduplexes were then 
digested by RNase A at 42°C. The digested fragments were analyzed by 
polyacrylamide gel electrophoresis under denaturing conditions and subse-
quent autoradiography. 
In this experimental design, only perfectly matching test RNA derived 
from the tumor-specific TCR-y gene rearrangement protects the probe 
RNA from I~ase digestion over the full length of the RNA heteroduplex. 
The presence of MF cells in the ACD specimen is therefore indicated by the 
detection of probe molecules corresponding in size to the full length of tlus 
duplex. The exact size of this fragment can be predicted from the size of me 
undigested probe and the relative positions of the primers used to synthesize 
the probe and test RNAs. Titration studies using normal bone marrow cells 
have shown a sensitivity limit of 10- 5 for detection of the tumor c1ol1e-
specific scqucnce (Veelken ef ai, 1995). 
RESULTS 
PCRlDGGE Detects Tumor Clone in MF but Not in Other 
Specimens Both patients showed clonal band patterns in their 
MF specimens by PCR/DGGE using Vyl-8 primers. In addition, 
Patient 2 showed a Vy9 clonal band pattern in her MF specimen. In 
contrast, there was no detectable clonal band pattern in the ACD or 
blood specimen s obtained from either case. As in some normal skin 
biopsies lacking sufficient T ce ll s bearing Vyl-8/]y1-2 TCR-'Y 
gene rearrangements, the normal skin specimen from Patient 1 
showed no detectable TCR-y PCR products by eith er agarose 
minigel ana lysis or DGGE. Representative PCR/DGGE results are 
iJlustrated in Fig 1. The first three lanes represent blood, MP, and 
ACD samples, respectively, from Paticnt 1. A distinct clonal band 
pattern is present only in the MF specim en (lalle 2). Lalles 4-7 
represent samples from Patient 2. Lalles 4 and 5 show a polyclonal 
pattern in the ACD sample analyzed for Vyl-8 and Vy9 rearrange-
ments, respectively. Lalles 6 and 7 show a dominant clonal pattern 
in the MF sample analyzed for Vy1-8 and Vy9 rearrangements, 
respectively. La/les 8 and 9 represent a negative control showing a 
polyclonal pattern for Vy1-8 and Vy9, respectively, in an unrelated 
case of cutaneous lymphoid h yperp lasia. 
PCRJRPA Detects Tumor Clone in MF and ACD but Not in 
Other Specimens Both patients showed a tumor-specific, rear-
ranged TCR-y gene sequence in their MF and ACD lesions by the 
PCR/RPA assay. In contrast, these was no detectable tumor-
specific sequ ence in theif blood specimens. As noted above, dle 
normal skin specimen from Patient 1 lacked TCR-y PCR product 
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Figure 2. PCRlRPA detects identical clonal TCR-'Y gene rear-
rangements in MF and ACD lesions obtained from Patient 1. See 
text for details. CTCL. cutaneous T-cell lymphoma; PBMC. peripheral 
blood mononuclear cells. Undig. probe. undigested RNA probe. The 
arrowhend points to the tllmor-specific RNA fragment protected from 
digestion by the complementary tllmor-specific I~A probe. 
involving V'YI-8 and J'Y1-2. Therefore, it was not subjected to 
clonal analysis by PCR/RPA. 
Figure 2 demonstrates the results of the analysis of Patient 1. 
The probe (not subjected to hybridization and RNA digestion, lalle 
15) contains a strong clonal component corresponding to the tumor 
as well as a smear around the clonal band that presumably 
represents reactive lymphocytes frequently found in lesions of MF. 
When hybridized to test RNA synthesized from the same (lillie 1) 
or a different (talle 7) MF lesion of this patient, a strong protected 
band in the expected position can be detected (an·ol/l). A band of 
roughly similar intensity is present in the same position when test 
RNA from the ACD lesion is analyzed (tn/Ie 8). Absence of tillS 
band in the lanes representing four control PEMC (tOiles 10-13) 
indicates the specificity of the protection from RNase digestion for 
the tumor-specific rearrangement. Absence of the same band in the 
lane ofPEMC from the patient (Iolle 9) demonstrates that the signal 
in the ACD specimen is not merely due to a ubiquitous presence of 
the circulating malignant T-cell clone. Parallel analysis oflogarith-
mic dilutions of DNA fiom the diagnostic specimen into normal 
PEMC DNA (talles 2-6) allows an approximate comparison of the 
degree of involvement of the ACD lesion by cells of the malignant 
clone. 
PCR/RPA applied to samples obtained from Patient 2 showed 
results simi.lar to those of Patient 1 except that the concentration of 
tumor cells within the ACD lesion was lower. As shown ill Fig 3, 
a fully protected band was visible in the lane corresponding to the 
ACD lesion (fallc 6); however, its intensity was much reduced when 
compared to the diagnostic MF biopsy. The respective intensities of 
the bands of the ACD specimen and of the dilutions of DNA £i'om 
the diagnostic MF sample (tal/es 1-5) indicated that the density of 
malignant T cells present in the ACD was approximately 0.1% of 
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Figure 3. PCRlRPA detects identical clonal TCR-'Y gene rear-
rangements in MF and ACD lesions obtained frOln Patient 2. Sec 
text for details. See Fig 2 for abbreviations and explanation of the nm/II"Iend. 
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that found in the MF lesion. The tumor-specific band was not 
detectable in PBMC from Patient 2 (lane 7) or in four control 
PEMC (toiles 8- 11). 
DISCUSSION 
The results of the molecular biologic analyses performed in tills 
study indicate that ACD lesions induced in MF patients contain low 
levels of the malignant T-cell clone detectable by PCR/RPA but 
not by PCR/DGGE. Eased on the known sensitivity thresholds of 
these two assays, it is possible to estimate the MF tumor clone 
density in the ACD lesions to be within the 0.001-1 % range. 
In Patient 1, earlier Southern blot analysis of genomic DNA 
(Wood ef 01,1994) had failed to detect clonal TCR gene rearrange-
ments in the same MF patch lesion used to generate the PCR/RPA 
probe for the current study. This lack of detectable clonality by 
Southenl blotting is not uncommon in early MF, because the tumor 
clone density is often below the 1-5% sensitivity limit of this 
teclmique (Wood et ai, 1994). Given this information, the previ-
ously stated sensitivity limits of PCR/DGGE (10 - 3_10 - 2 ) and 
PCR/RPA (10 - 5), and the observation that tUlllor clone densities 
in Fig 2 were roughly similar foJ' the MF and ACD lesions, we can 
estimate that the absolute density of tumor cells in both the MF and 
ACD lesions of Patient 1 lies within the 0 .1-1 % range. 
Although Southern blotting was not performed on the MF lesion 
obtained for this study from Patient 2, prior quantitative studies 
indicated that thin plaques typical of her MF lesions contained 
approximately 25'Yo T-cell DNA (Wood ef 01,1991). Ifwe assume 
that tillS is her maximum tumor cell density, then given the results 
of her PCR/DGGE and PCR/RPA analyses, which show about a 
I,OOO-fold difference between the relative density of the tumor 
clone in the MF and ACD lesions (see Fig 3), we can estimate that 
the absolute tumor clone density within the ACD lesion lies within 
the 0.001-0.025% range. The lower density of tumor cells in the 
ACD lesion of Patient 2 relative to Patient I may reflect the longer 
duration of her MF and the cumulative effects of treatment on the 
functional capabilities of her tumor clone. Alternatively, it may 
reflect an inherent functional difference in her tumor. It is not due 
to a relative anergy to mechlorethamine, because the overall 
clinical extent of her ACD reaction was similar to that of Patient 1. 
It is tempting to speculate that allergens other than mechloreth-
amine might have induced a greater density of MF cells within the 
ACD lesions, because they would lack the chemotherapeutic effects 
of tillS allergen . 
T he absence of detectable tumor within the blood of both MF 
patients indicates that the presence of tumor cells within the ACD 
lesions was not due merely to the ubiquitous presence oflow-Ievel 
circulating tumor cells. Instead, it suggests that there had been 
selective trafficking of tumor cells into the skin of these patients at 
the site of ACD. TillS interpretation is also supported by the 
absence of detectable TCR-'Y gene rearrangements involving 
V'Y1-8 and J'Y1-2 in the nornlal skin biopsy obtained from Patient 
1. Although it is not possible to exclude the presence of occult 
tumor cells in other clinically nomlal skin locations, tillS absence of 
TCR-'Y PCR products argues that the normal skin of Patient 1 was 
not a reservoir for occult MF that was incidentally detected during 
analysis of the ACD lesion. Alternatively, it is possible that vety rare 
MF tumor cells were present in the 110rmal skin and proliferated to 
a detectable level in response to cytokines released during the 
genesis of the ACD reaction. 
Studies of ACD have shown that most of the lesional infiltrate is 
composed of T cells nonspecificaJ1y recruited to the site by a small 
vanguard of antigen-specific T cells. TIllS vanguard is present at a 
maximum estimated density of 0.02-0 .1% (Kalish and jolmson, 
1990) . Since each antigen generally contains multiple distinct 
epitopes, each clone of antigen-specific T cells is probably at a 
density of about 10-fold lower than tillS range (Mielke el al. 1994). 
In MF patients with ACD lesions, it is probable that the nonspe-
cifically recruited, polyclonal T cells contain low levels of the MF 
tumor clone itself. This is not surprising given the well-differenti-
ated CD4 + CD45RO + CLA + SALT I memory T-cell phenotype of 
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most MF cases and the well known functional ability of MF tumor 
cells to traffic into the papillary dermis and epidermis-the same 
sites of T-cell infiltration seen in ACD. 
N evertheless, our fll1dings should be regarded as being prelimi-
nary until additional cases can confirm them and perhaps extend 
them to other allergens. It will also be of interest to determine the 
tumor clone status of blood obtained at multiple time points and 
normal skin obtained at multiple sites during development of the 
ACD lesions . T he clonality of the ACD sites at various times 
following their clinical resolution will also be important to deter-
mine. 
Aside from providing new insights into the functional capabilities 
ofMF tumor cells, the current study also complements prior studies 
of the molecular staging of MF patients using PCR/RPA (Veelken 
et ai, 1995). T hese earlier studies showed detectable tumor cells in 
100% of specimens including four morphologically uninvolved 
blood samples. T he lack of detectable tumor in the blood specimens 
from the two MF patients in the current study indicates that tumor 
recognized by PCR/RPA is not ubiquitous in MF patients. If 
circulating tumor ceLI s were present in these patients, the extent of 
blood involvem ent would have been below the 10- 5 sensitivity 
threshold of PCRlRPA. T his raises the possibility that molecular 
staging may provide prognostically significant information by de-
termining the extent of tumor dissemination in MF patients more 
accurately than is possible using morphologic criteria. 
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